Attached files
| file | filename |
|---|---|
| EX-31.2 - CERTIFICATION - NMI Health, Inc. | name_ex312.htm |
| EX-32.1 - CERTIFICATION - NMI Health, Inc. | name_ex321.htm |
| EX-32.2 - CERTIFICATION - NMI Health, Inc. | name_ex322.htm |
| EXCEL - IDEA: XBRL DOCUMENT - NMI Health, Inc. | Financial_Report.xls |
| EX-31.1 - CERTIFICATION - NMI Health, Inc. | namn_ex311.htm |
U. S. SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 10-Q
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: March 31, 2013
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period From ________ to_________
Commission File No. 000-27421
NANO MASK, INC.
(Exact Name of Small Business Issuer as Specified in its Charter)
|
NEVADA
|
87-0561647
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
50 West Liberty Street, Suite 880, Reno, NV
|
89501
|
|
(Address of principal executive offices)
|
(Zip code)
|
Issuer's telephone number, including area code: (209) 275-9270
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
(1) Yes þ No ¨ (2) Yes þ No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company þ
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ
State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:
At May 24, 2013, there were outstanding 98,695,444 shares of the Registrant's Common Stock, $.001 par value.
2
FINANCIAL INFORMATION
|
Page
|
|
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
|
|
9
|
|
|
11
|
|
|
11
|
|
|
|
|
|
12
|
|
|
12
|
|
|
12
|
|
|
12
|
|
|
12
|
|
|
13
|
|
|
14
|
|
March 31,
|
December 31,
|
|||||||
|
2013
|
2012
|
|||||||
|
ASSETS
|
||||||||
|
CURRENT ASSETS
|
||||||||
|
Cash
|
$ | 4,405 | $ | 9,409 | ||||
|
Accounts receivable, net
|
1,514 | - | ||||||
|
Other receivable
|
7,553 | - | ||||||
|
Prepaid expenses
|
55,883 | - | ||||||
|
Inventory, net
|
41,553 | 42,165 | ||||||
|
Total current assets
|
110,908 | 51,574 | ||||||
|
FIXED ASSETS
|
||||||||
|
Equipment and molds
|
973 | 973 | ||||||
|
Accumulated depreciation
|
(533 | ) | (519 | ) | ||||
| 440 | 454 | |||||||
|
OTHER ASSETS
|
||||||||
|
Non-performing assets
|
4,230 | 4,230 | ||||||
|
Total assets
|
$ | 115,578 | $ | 56,258 | ||||
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
||||||||
|
CURRENT LIABILITIES
|
||||||||
|
Customer advances
|
$ | 63,744 | $ | 12,545 | ||||
|
Accounts payable
|
413,184 | 449,331 | ||||||
|
Accounts payable – related party
|
5,563 | 10,380 | ||||||
|
Advances from related party
|
285,200 | 207,200 | ||||||
|
Accrued expenses
|
806,452 | 687,336 | ||||||
|
Notes payable
|
521,157 | 521,157 | ||||||
|
Note payable – related party
|
25,000 | 25,000 | ||||||
|
Total current liabilities
|
2,120,300 | 1,912,949 | ||||||
|
Total liabilities
|
2,120,300 | 1,912,949 | ||||||
|
STOCKHOLDERS' DEFICIT
|
||||||||
|
Common stock, $0.001 par value, 100,000,000 shares authorized; 98,695,444 shares outstanding in 2013 and 2012
|
98,695 | 98,695 | ||||||
|
Additional paid-in capital
|
21,624,265 | 21,624,265 | ||||||
|
Accumulated deficit
|
(23,727,682 | ) | (23,579,651 | ) | ||||
|
Total stockholders’ deficit
|
(2,004,722 | ) | (1,856,691 | ) | ||||
|
Total liabilities and stockholders’ deficit
|
$ | 115,578 | $ | 56,258 | ||||
The accompanying notes are an integral part of these unaudited financial statements.
NANO MASK, INC.
For the Three Months Ended March 31, 2013 and 2012
(Unaudited)
|
2013
|
2012
|
||||||||
|
NET SALES
|
$ | 23,004 | $ | 218,350 | |||||
|
COSTS AND EXPENSES
|
|||||||||
|
Cost of goods sold
|
14,131 | 138,913 | |||||||
|
Research and development
|
- | 115 | |||||||
|
Selling, general and administrative
|
199,104 | 206,613 | |||||||
| 213,235 | 345,641 | ||||||||
|
LOSS FROM OPERATIONS
|
(190,231 | ) | (127,291 | ) | |||||
|
OTHER INCOME (EXPENSE)
|
|||||||||
|
Gain on settlement of vendor liabilities and other
|
52,973 | 2,365 | |||||||
|
Interest expense
|
(10,773 | ) | (10,623 | ) | |||||
|
Total other income (expense)
|
42,200 | (8,258 | ) | ||||||
|
NET INCOME (LOSS)
|
$ | (148,031 | ) | $ | (135,549 | ) | |||
|
BASIC AND FULLY-DILUTED INCOME (LOSS) PER SHARE
|
$ | (0.00 | ) | $ | (0.00 | ) | |||
|
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
|
98,695,444 | 86,625,468 | |||||||
The accompanying notes are an integral part of these unaudited financial statements.
|
NANO MASK, INC.
For the Three Months Ended March 31, 2013 and 2012
(Unaudited)
|
||||||||
|
2013
|
2012
|
|||||||
|
|
||||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net income (loss)
|
$ | (148,031 | ) | $ | (135,549 | ) | ||
|
Adjustments to reconcile net income (loss) to net cash used in operating activities:
|
||||||||
| Depreciation | 14 | 167 | ||||||
|
Common stock issued for services
|
- | 164,126 | ||||||
|
Gain on settlement of vendor liabilities
|
(26,000 | ) | (2,365 | ) | ||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(1,514 | ) | 272 | |||||
|
Other receivable
|
(7,553 | ) | - | |||||
|
Inventory
|
612 | 186 | ||||||
|
Prepaid expenses
|
(55,883 | ) | (30,574 | ) | ||||
|
Customer advances
|
51,199 | (59,951 | ) | |||||
|
Accounts payable
|
(10,147 | ) | (165 | ) | ||||
|
Accrued expenses
|
119,116 | (36,376 | ) | |||||
|
Net cash used in operating activities
|
(78,187 | ) | (100,229 | ) | ||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Proceeds from issuance of common shares
|
- | 25,000 | ||||||
|
Proceeds from issuance of short-term note payable
|
- | 5,149 | ||||||
|
Proceeds from advances of related parties
|
73,183 | 9,419 | ||||||
|
Repayments of short-term note payable
|
- | (843 | ) | |||||
|
Net cash provided by financing activities
|
73,183 | 38,725 | ||||||
|
NET DECREASE IN CASH
|
(5,004 | ) | (61,504 | ) | ||||
|
CASH AT BEGINNING OF PERIOD
|
9,409 | 61,504 | ||||||
|
CASH AT END OF PERIOD
|
$ | 4,405 | $ | - | ||||
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
|
||||||||
|
Cash paid for interest
|
$ | - | $ | 36 | ||||
|
Cash paid for income taxes
|
$ | - | $ | - | ||||
|
NON-CASH INVESTING AND FINANCING ACTIVITIES
|
||||||||
|
Common stock issued for settlement of advances from related parties
|
$ | - | $ | 8,703 | ||||
|
Common stock issued for settlement of accounts payable
|
$ | - | $ | 5,735 | ||||
The accompanying notes are an integral part of these unaudited financial statements.
NANO MASK, INC.
For the Three Months Ended March 31, 2013
NOTE 1 - BASIS OF PRESENTATION
The financial information included herein is unaudited and has been prepared consistent with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8, Rule 8.03 of Regulation S-K. Accordingly, these financial statements do not include all information required by generally accepted accounting principles for annual financial statements. These statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2012, from which the balance sheet information at that date is derived and reference is made thereto elsewhere in this report. These interim financial statements contain all adjustments necessary in the opinion of management for a fair statement of results for the interim periods presented.
The results of operations for the three months ended March 31, 2013, are not necessarily indicative of the results to be expected for the full year.
Certain minor reclassifications in prior period amounts have been made to conform to the current period presentation.
NOTE 2 – GOING CONCERN
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, in addition to a working capital deficiency at March 31, 2013, the Company has incurred negative cash flow from operations and significant losses, which have substantially increased its operating deficit at March 31, 2013. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The Company’s ability to continue as a going concern will be dependent upon economic developments and the success of management's plans as set forth below, which cannot be assured. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. Management and board members are continuing to discuss other alternative financing options, but no definitive proposals or agreements have been reached.
The foregoing notwithstanding, management does not believe the Company currently has sufficient capital to sustain its planned business activities for the next twelve months following the issuance of these financial statements. Accordingly, while management has historically been successful generating sufficient funds to sustain operations, there is no assurance that they will continue to do so. Nevertheless, the Company will seek additional capital to sustain its operations, either through additional private placements of common stock or loans, possibly unsecured, until such time as its operations are self-sustaining. These funds will be required to continue the Company’s efforts to generate sales of its products and to provide sufficient working capital to meet the expected sales demand.
NOTE 3 – SIGNIFICANT TRANSACTIONS
The Company realized a gain of $26,973 from disposition of common shares in Medmarc Insurance Company which was a mutual insurance company that was bought by another company. Since the Company had maintained its insurance through Medmarc, the Company was designated a percentage of the final sales proceeds from the sale of Medmarc. $7,553 was withheld as Federal income taxes and is reflected as other receivable. In addition, the Company realized a gain of $26,000 from debt expiry under the Statute of Limitations during the three months ended March 31, 2013.
During the three months ended March 31, 2013, the Company received $73,183 of cash advances from four executive officers without specific repayment terms. The similar period of 2012 amounted to $9,419.
NANO MASK, INC.
Notes to Financial Statements (Unaudited)
For the Three Months Ended March 31, 2013
NOTE 4 - SUBSEQUENT EVENTS
Subsequent to March 31, 2013, the Company received $61,000 from a key officer.
On or about May 30, 2013, the Company has announced that it is changing its name to NMI Health, Inc. and recording a reverse split of its common stock of 1 share for every 10 shares held.
NOTE 5 – CONTINGENCIES
On March 5 2012, the Company received a complaint from a certain attorney seeking collection of his invoices in the amount of $167,167, plus interest and litigation expenses. The Company believes the likelihood of loss in this case is remote and has requested dismissal of the charges. The Company has already recognized $15,763 as a liability at March 31, 2013. The Company is awaiting an amendment by the plaintiff of his claim.
On or about May 8, 2012, the Company received a complaint from a certain former employee seeking collection of his charges as a distributor and as an employee in the amount of $409,525, plus interest and litigation expenses. The Company believes the likelihood of loss in this case is remote and intends to offset for certain expenditures made by the Company caused by employee. The Company has already recognized $37,500 as a liability at March 31, 2013.
On December 29, 2010, the Company received a complaint from Applied Nanoscience, Inc. seeking collection of the as yet unpaid notes payable to Applied in the amount of $453,500, plus interest and litigation expenses. On February 1, 2011, the Company countersued for breach of contract and related claims. The Company maintains a right of offset in the amount of $41,360 against Applied’s notes and is reflected on the balance sheet in the net amount of $412,140. This case will be tried in July, 2013.
Cautionary Statement Regarding Forward-looking Statements
This report may contain "forward-looking" statements. Examples of forward-looking statements include, but are not limited to: (a) projections of revenues, capital expenditures, growth, prospects, dividends, capital structure and other financial matters; (b) statements of plans and objectives of our management or Board of
We are a materials-technology development company focused on health and wellness-related markets. The Company has evolved from a specialty filter products Company that developed a state-of-the-art air filtration technology for removing infectious bacteria and viruses in air flow systems into a Company providing a proprietary line of antibacterial and antimicrobial products for the hospital, clinic and health industry. Such products now include our Nano Zyme line of products which offer a multi-enzyme hospital pre-soak and cleaning solution, as well as other complementary products in the line. Another line of products surrounds our new Nano Silver Hospital Curtains which offer excellent anti microbial efficacies against a wide spectrum of organisms. These products have been developed by partnering with innovative technology companies. The new product lines are in addition to our traditional anti-viral, antibacterial and disposable mask, a protective filtration face mask which we continue to improve upon.
Since its inception, the Company has been involved in the development of its technology. Through March 31, 2013, revenues have not been adequate to cover operating expenses and thus, the Company has reported a loss in each of its years of existence. As of the current report date, the Company has funded itself through a series of private equity placements and unsecured loans which has offset its accumulated equity deficit in this manner.
Results of Operations for the Three Months Ended March 31, 2013 compared with 2012
Revenues: For the three months ended March 31, 2013, revenues amounted to only $23,004, solely from sale of our SilverCare Plus™ scrubs and curtains for hospital use. During the three months ended March 31, 2012, revenues amounted to $218,350 of which virtually all sales represented our SilverCare Plus™ products. Sales were lower primarily due to the timing in our receipt of sales orders.
Cost of Sales: The related Cost of sales during the three months ended March 31, 2013 amounted to $14,131 and $138,913, respectively, which provided gross margins of 38.6% and 36.4%. The higher margins are largely attributable to lower production costs.
Operating Expenses: During the three months ended March 31, 2013, the Company has experienced an approximate $8,000 decrease in general and administrative expenses or an approximate 3.6% decrease from levels reported in the similar period of 2012. This is largely due to reduced audit fees ($30,000) offset by higher website development ($15,000), telephone ($5,000) and travel ($4,000)expenses.
Other Income: For the three months ended March 31, 2013, we reported other income of $42,200 from $26,973 of gains recorded on disposition of a mutual insurance company and $26,000 of gains from expiry under the State of Limitations, offset by interest expenses of $10,773. For the three months ended March 31, 2012, we reported other expense of $8,258, consisting primarily of a gain on settlement of outstanding liabilities offset by interest expense.
Research and development: Research and development (R&D costs) relates to product development efforts and includes related FDA testing. While there were no R & D costs for the three months ended March 31, 2013, only $115 of R&D costs was incurred in the three months ended March 31, 2012. If resources are available in the future, the Company intends to bring additional products to market, assuming those products are still viable at the time the resources are available. The significant components of the Company’s research and development costs ordinarily include prototype development and materials, governmental filings and laboratory testing.
Net Loss: We experienced a net loss of $148,031 for the three months ended March 31, 2013 compared to net loss of $135,549 in the prior year. The increase in net loss during 2013 was primarily due to approximately $70,000 lower gross margins from approximately $195,000 lower sales offset in large part by approximately an approximate $50,000 increase from other income noted above.
Liquidity and Capital Resources
We have not been able to generate sufficient net cash inflows from operations to sustain our business efforts as well as to accommodate our growth plans. Cash used in our financing activities for the three months ended March 31, 2013 and 2012 was funded primarily by the sale of common stock for cash and from cash advances by key officers. During 2013, the Company received net cash advances from four executive officers for $73,183 compared with $9,419 in 2012. Also, while the Company received no further funds through stock issuances or issuance of notes payable during 2013, the Company received $25,000 in cash through its private placement with two investors for 1,000,000 shares of common stock during 2012.
Cash Flows from Operating Activities: The cash outflow totaled $78,187 in the three months of 2013 compared to a cash outflow of $100,229 in 2012. This is primarily attributable to an increase of $119,116 in accrued expenses offset by $70,564 in lower gross margins from approximately $195,000 lower sales than in 2012.
Cash Flows from Investing Activities: No cash was used in investing activities during the three months of 2013 or 2012.
Cash Flows from Financing Activities: Cash flows from financing activities in the three months of 2013 totaled $73,183. The Company was able to obtain $73,183 in net cash advances from four key officers. In 2012, the Company received $25,000 from the issuance of common stock for cash, $4,306 from a short term note, net of re-payments and $9,419 from net cash advances from key officers.
Management and board members are continuing to discuss other alternative financing options, but no definitive proposals or agreements have been reached.
Beginning in the third quarter of 2008, the United States has been experiencing a severe and widespread recession accompanied by, among other things, instability in the financial markets and reduced credit availability, all of which are likely to continue to have far reaching effects on economic activity in the country for an indeterminate period. The effects and probable duration of these conditions and related risks and uncertainties on the Company's ability to obtain financing, success in its marketing efforts and ultimately, profitable operations and positive cash flows, cannot be estimated at this time.
The Company does not believe, however, that it currently has sufficient capital to sustain its business efforts for the next twelve months. Accordingly, the Company will need to raise additional capital in the near future to sustain operations. The Company is also working on minimizing operating expenses, to the extent possible, by reducing overhead costs, salaries, and other consulting and professional fees, in order to conserve available cash.
Accordingly, for these and other reasons, there is significant uncertainty regarding the Company’s future, and the Company’s auditors expressed substantial doubt as to the Company’s ability to continue as a going concern in their report on the Company’s 2012 audited financial statements.
Impact of Inflation
At this time, the Company does not expect that inflation will have a material impact on its current or future operations.
Critical Accounting Policies and Estimates
Except with regard to the estimated useful lives of patents and acquired technology, the net realizable value of the Company’s inventory due to shelf-life issues and design, the allowance for bad debts on accounts receivable, and the effective provision of a 100% deferred income tax asset valuation allowance, the Company does not employ any critical accounting policies or estimates that are either selected from among available alternatives or require the exercise of significant management judgment to apply or that if changed are likely to materially affect future periods.
Management reviews the carrying value of the technology assets annually based on its current marketing activities, plans and expectations, and the perceived effects of competitive factors and possible obsolescence, whether any write-downs should be taken or whether the estimated useful lives should be shortened.
Management also reviews the carrying value of its inventory periodically for evidence of declines in estimated fair value and considers, based on its current marketing activities, plans and expectations, and the perceived effects of competitive factors and possible obsolescence due to shelf-life issues on the environmental filters, whether any write-downs should be taken.
Management also reviews the collectability of outstanding receivables based upon historical collection history from each customer, the age of the receivables, and the customers wherewithal to pay the outstanding balance, and records an estimated allowance for bad debts sufficient to cover any potential losses to be incurred for non-collections.
Recent Accounting Pronouncements
While there have been FASB pronouncements made effective subsequent to the issuance of these financial statements, none would have required restatement of the financial statements herein nor have they had any significant effect on future financial statements of the Company.
Smaller reporting companies are not required to provide the information required by this item.
We maintain a system of disclosure controls and procedures that are designed for the purpose of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Chief Executive Officer and the Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosures.
For the period ended March 31, 2013, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Exchange Act. In the course of this evaluation, our management considered the material weakness in our internal control over financial reporting as discussed in our Annual Report on Form 10-K for the period ended December 31, 2012. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of the end of the period covered by this report on Form 10-Q, our disclosure controls and procedures were not effective to ensure that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the registrant’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. To overcome this weakness, our principal executive and financial officers have reviewed and provided additional substantive accounting information and data in connection with the preparation of this quarterly report. Therefore, despite the weaknesses identified, our principal executive and financial officers believe that there are no material inaccuracies or omissions of material facts necessary to make the statements included in this report not misleading in light of the circumstances under which they are made.
Changes in Internal Control over Financial Reporting
We will continue to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over financing reporting on an ongoing basis and are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.
There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2013 that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.
OTHER INFORMATION
On December 29, 2010, the Company received a complaint from Applied Nanoscience, Inc., a Nevada corporation, filed in the District Court of Clark County in Nevada (Case No. A-10-631192-C) and which seeks collection of notes payable to Applied in the amount of $453,500, including accrued interest and related legal expenses. On February 1, 2011, we countersued for breach of contract and claims related thereto. Our management believes that the value of its counterclaim will exceed the value of the claims asserted against the Company but cannot fully assess the outcome of the action at this time. Accordingly, management believes adequate provision has been made in the accompanying financial statements related to this complaint. The complaint will be tried in July, 2013.
On March 5, 2012, the Company received a complaint from a certain attorney seeking collection of his invoices, plus interest and litigation expenses of $167,167.25. The Company does not believe the claim has any merit and has requested dismissal of the charges. The claim, Case No. 110907934 DC, was filed in the Second District Court of Weber County in the State of Utah. The Company is awaiting an amendment to his complaint.
On or about May 8, 2012, the Company received a complaint from a certain former employee seeking collection of his charges as a distributor and as an employee in the amount of $409,525, plus interest and litigation expenses. Case No. CU12-01141 for the complainant was filed in the Second District Court of Washoe County in the State of Nevada. The Company does not believe that the claim has any merit and intends to offset for certain Company expenditures caused by the employee.
None.
None.
None.
|
Exhibit No.
|
Description
|
|
|
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
||
|
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
||
|
Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
||
|
Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
||
|
101.Ins
|
Xbrl Instance Document
|
|
|
101.Sch
|
Xbrl Taxonomy Extension Schema Document
|
|
|
101.Cal
|
Xbrl Taxonomy Extension Calculation Linkbase Document
|
|
|
101.Def
|
Xbrl Taxonomy Extension Definition Linkbase Document
|
|
|
101.Lab
|
Xbrl Taxonomy Extension Label Linkbase Document
|
|
|
101.Pre
|
Xbrl Taxonomy Extension Presentation Linkbase Document
|
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
NANO MASK, INC.
|
|||
|
May 24, 2013
|
|
/s/ Edward Suydam | |
| Edward Suydam, Chief Executive Officer | |||
|
May 24, 2013
|
|
/s/ Michael J. Marx | |
| Michael J. Marx, Chief Financial Officer | |||
14